Related Experiment Video
Updated: Apr 26, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Public Interest in Janus Kinase (JAK) Inhibitors for Alopecia Areata: A Google Trend Analysis
Jade Howard1, Nourine A H Kamili2, Hala Idris2
1Transitional Year Residency Program and BayCare Health System (Winter Haven), College of Medicine, Florida State University, 1201 1st St S, Suite 100A, Winter Haven, FL, 33880, United States, 1 (863) 280-6085.
Unlabelled:
Public interest in Janus kinase (JAK) inhibitors for alopecia areata increased following media coverage and the 2022 US Food and Drug Administration (FDA) approval of baricitinib, highlighting the need for patient education and physician guidance on appropriate indications and treatment selection for hair loss disorders.
Related Concept Videos
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Inhibition of CDK Activity
MAPK Signaling Cascades
cAMP-dependent Protein Kinase Pathways

